Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Teva Pharmaceutical Industries - SIC # 2834 - PHARMACEUTICAL PREPARATIONS
Ticker
Exchange
SIC #
Website
Latest Ticker
TEVA
New York
2834
https://www.tevapharm.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Teva Pharmaceutical Industries
A Week Of Fast-Moving Stocks Ahead: Disney, Toyota, Ferrari, Constellation
- May 3rd, 2024 9:58 pm
Unlocking Q1 Potential of Teva Pharmaceutical Industries (TEVA): Exploring Wall Street Estimates for Key Metrics
- May 3rd, 2024 1:15 pm
Teva to Present at the 2024 Bank of America Healthcare Conference
- May 2nd, 2024 10:30 pm
Corcept Therapeutics Incorporated (NASDAQ:CORT) Q1 2024 Earnings Call Transcript
- May 2nd, 2024 2:48 pm
Teva’s 2023 Healthy Future Report Showcases Renewed Sustainability Strategy and Ambitious Targets
- May 2nd, 2024 12:30 pm
Q1 2024 Corcept Therapeutics Inc Earnings Call
- May 2nd, 2024 12:01 pm
Corcept Therapeutics Inc (CORT) Q1 2024 Earnings Call Transcript Highlights: Strong Growth Amid ...
- May 2nd, 2024 7:41 am
U.S. Commercialization Agreement with Quallent to Drive Patient Savings with First High-Concentration Citrate-Free Interchangeable Biosimilar to Humira® (adalimumab)
- Apr 30th, 2024 8:00 am
UPDATE 1-U.S. Supreme Court rejects Vanda Pharmaceuticals case over sleep-drug patents
- Apr 22nd, 2024 3:37 pm
11 Best Low Price Pharma Stocks To Invest In
- Apr 21st, 2024 2:39 pm
Zacks Industry Outlook Highlights Teva, Dr. Reddy's and Viatris
- Apr 19th, 2024 10:00 am
3 Generic Drug Stocks to Watch Amid Challenging Market Prospects
- Apr 18th, 2024 3:12 pm
Alvotech and Teva Announce U.S. FDA Approval of SELARSDI™ (ustekinumab-aekn), biosimilar to Stelara® (ustekinumab)
- Apr 16th, 2024 9:43 pm
Teva’s New Real-World Evidence Presented at the 2024 AAN Annual Meeting Confirms Effectiveness and Patient Satisfaction for HD Chorea with the 4-week Titration Kit for AUSTEDO® (deutetrabenazine) Tablets
- Apr 16th, 2024 12:00 pm
Israeli economy has proven to thrive despite crisis: Expert
- Apr 15th, 2024 9:21 pm
Teva Confirms Efficacy and Safety of AJOVY® (fremanezumab) for the Prevention of Migraine With Results from Phase 3 Trial in China
- Apr 11th, 2024 12:30 pm
Teva to Host Conference Call to Discuss First Quarter 2024 Financial Results at 8 a.m. ET on May 8, 2024
- Apr 9th, 2024 8:30 pm
New Pharmacokinetic Modeling Data Presented by Teva Simulates Clinical Profiles of Schizophrenia Patients Switching to UZEDY® (risperidone) Extended-Release Injectable Suspension at SIRS 2024
- Apr 6th, 2024 5:00 pm
Teva and mAbxience Announce Strategic Global Licensing Agreement for Oncology Biosimilar Candidate
- Apr 4th, 2024 12:30 pm
3 No-Brainer Stocks to Buy With $600 Right Now
- Apr 3rd, 2024 9:21 am
Scroll